Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Deals report: Merck buying Buffalo academic spinout to enhance ADCs

Plus more antibody-drug conjugate deals: Ipsen-Sutro, Merck KGaA-Caris

By Paul Bonanos, Director of Biopharma Intelligence, and Gunjan Ohri, Data Content Analyst
April 9, 2024 12:18 AM UTC

Merck is acquiring a University at Buffalo spinout for up to $208 million to improve the performance of antibody-drug conjugates in its pipeline.

An announcement by the State University of New York institution did not include the upfront payment, but said the takeout of Abceutics Inc. by Merck & Co. Inc. (NYSE:MRK) includes milestones tied to “the progress of candidates.”...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Caris Life Sciences Inc.

Ipsen Group

Merck & Co. Inc.

Merck KGaA

Sutro Biopharma Inc.